Pharmacy

Dispensing of buprenorphine — the first medication to treat opioid use disorder that can be prescribed in physician offices — through retail pharmacies remained higher in rural counties than in urban counties from 2019 to 2025, while emergency department adoption…

Walmart has agreed to pay $50 million to resolve allegations that its pharmacies illegally filled thousands of invalid prescriptions for opioids and other controlled substances in violation of the Controlled Substances Act. The Justice Department alleged that Walmart’s compliance team…

The FDA cleared Amygdala Neurosciences’ Investigational New Drug application for ANS-858, allowing the company to move the drug into clinical development. ANS-858, the company’s lead clinical candidate, is a selective, reversible, orally bioavailable inhibitor of aldehyde dehydrogenase 2 (ALDH2), according…

The FDA approved Simtriyo (centanafadine), making it the first and only approved norepinephrine, dopamine, serotonin reuptake inhibitor (NDSRI) for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients aged 6 years and older weighing at least 20…

Eli Lilly and Co. has agreed to acquire AtaiBeckley, a clinical-stage biopharmaceutical company developing innovative therapeutics for mental health conditions, to advance the drugmaker’s push into psychedelic-based research. The acquisition comes as the federal government has pursued actions to advance…

Maryland pharmacists will gain expanded authority to participate in opioid use disorder treatment under a new state law taking effect July 1. House Bill 838 eliminates the requirement that authorized prescribers submit prescriber-pharmacist agreements to the applicable health occupations board.…

More than 14,700 bottles of Duloxetine — commonly prescribed for individuals with depression and anxiety conditions — were recalled nationwide after the antidepressant was found to contain N-nitroso-duloxetine impurity above the FDA’s recommended interim limit.  Breckenridge Pharmaceutical initiated a voluntary…

In 2024, nearly 30% of residents in Massachusetts with commercial insurance filled a prescription to treat a behavioral health condition, as diagnoses and medication usage increased across all demographics, WWLP reported June 11.  Here are four things to know:

Grand Mental Health, a Tulsa, Okla.-based behavioral health organization, has officially entered the pharmacy space — a move its leadership says is both a financial strategy and a direct extension of its mission to serve some of Oklahoma’s most underserved…

The White House is preparing an executive order to expand federal research into ibogaine, a psychedelic drug used in some countries to treat PTSD, CBS News reported April 16.  The Trump administration plans to keep ibogaine classified as a Schedule…